Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22769033 | 0.90 | EPHX2 (0.50) | EPHX2PPARGCYSLTR1 | |
| SCHEMBL22768815 | 0.87 | EPHX2 (0.49) | EPHX2PPARGCYSLTR1CYSLTR2POLB | |
| SCHEMBL22768989 | 0.86 | CDK2 (0.52) | PLA2G4ALTB4RCDK2POLBLMNA | |
| SCHEMBL22769013 | 0.85 | CDK2 (0.47) | PLA2G4ALTB4RCDK2POLBLMNA | |
| SCHEMBL22768816 | 0.76 | EPHX2 (0.52) | EPHX2PPARGCYSLTR1 | |
| SCHEMBL28391587 | 0.75 | PLA2G4A (0.56) | HPGDPLA2G4ALTB4RCDK2POLB | |
| SCHEMBL9586130 | 0.74 | — | — | |
| SCHEMBL22768299 | 0.73 | KMT2A (0.51) | CYSLTR1CYSLTR2L3MBTL1MMP2MMP9 | |
| SCHEMBL13772378 | 0.73 | PLA2G4A (0.53) | PLA2G4ALTB4RCDK2LMNAMAPT | |
| SCHEMBL22768294 | 0.73 | KDM4E (0.51) | PLA2G4APOLBLMNAMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136598-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND METHODS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-20230136598-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND METHODS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-11535592-B2 | Antimicrobial compounds, compositions, and method | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-12-27 | — | — | US | disclosed |
| US-20200385348-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND METHODS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136598-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND METHODS | LPO, GPX4, GMPS | EPHX2 3033/4885PPARG 283/4885CYSLTR1 887/4885 |
| US-11535592-B2 | Antimicrobial compounds, compositions, and method | LPO, MPO, GMPS | EPHX2 3105/4885PPARG 276/4885CYSLTR1 955/4885 |
| US-20200385348-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND METHODS | LPO, GPX4, GMPS | EPHX2 3033/4885PPARG 283/4885CYSLTR1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.